HAUPPAUGE, N.Y., Aug. 07, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from $2,838,225 in 2025 to $3,108,267 in 2026, with net income increasing 16% from $626,826 ($0.14 per share) to $728,579 ($0.16 per share). Net sales for the six-month period ended June 30th increased by 12% from $5,319,352 in 2025 to $5,980,489 in 2026, and net income increased by 30% from $1,187,721 ($0.26 per share) to $1,547,481 ($0.34 per share).
Donna Vigilante, President of United-Guardian, stated, “I am pleased to report that sales and earnings increased in both the second quarter and first half of 2026. Sales of our cosmetic ingredients and pharmaceutical products increased during both periods compared with the same periods in 2025. Cosmetic ingredient sales increased by 44% in the second quarter and 34% in the first half of 2026 compared with the same periods in 2025. The growth in cosmetic ingredient sales was primarily attributable to increased purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. ASI had experienced higher-than-normal inventory levels in 2025, which have since been reduced, resulting in the resumption of regular purchasing levels in the first half of 2026. Pharmaceutical sales increased by 1% in the second quarter and 11% in the first half of 2026 compared with the same periods in 2025, with Renacidin®, our most important pharmaceutical product, serving as the primary driver of growth.”
“As we move through 2026, we remain focused on our growth plan, which includes expanding promotional efforts and increasing market awareness for Renacidin, particularly among physicians and care providers; increasing awareness of our “natural” products; and growing our medical lubricant business.”
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
Contact:Donna Vigilante (631) 273-0900 [email protected]
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
Three and Six Months Ended
June 30, 2026 and 2025
STATEMENTS OF INCOME
(unaudited)
THREE MONTHS
ENDED JUNE 30, SIX MONTHS
ENDED JUNE 30, 2026 2025 2026 2025 Net sales$3,108,267 $2,838,225 $5,980,489 $5,319,352 Costs and expenses: Cost of sales 1,562,465 1,340,854 3,010,254 2,463,930 Operating expenses 667,282 694,050 1,334,245 1,326,785 Research and development
expense 124,395 107,868 239,416 222,262 Total costs and expenses 2,354,142 2,142,772 4,583,915 4,012,977 Income from operations 754,125 695,453 1,396,574 1,306,375 Other income: Investment income 70,445 70,573 140,259 155,260 Net gain on marketable
securities 48,365 24,576 66,107 36,926 Settlement income 36,360 --- 339,493 --- Gain on sale of asset 8,310 --- 8,310 --- Total other income 163,480 95,149 554,169 192,186 Income before provision
for income taxes 917,605 790,602 1,950,743 1,498,561 Provision for income taxes 189,026 163,776 403,262 310,840 Net income$728,579 $626,826 $1,547,481 $1,187,721 Earnings per common share
(basic and diluted)$0.16 $0.14 $ 0.34 $ 0.26 Weighted average shares
(basic and diluted) 4,594,319 4,594,319
4,594,319
4,594,319